Moderate Hepatic ImpairmentPhase 1NCT04995484

A Study of Belzutifan (MK-6482) in Participants With Hepatic Impairment (MK-6482-020)

A Phase 1 study testing Belzutifan in people with Moderate Hepatic Impairment, run by Merck Sharp & Dohme LLC at 2 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Who is it for?: Ages 18 to 75 yearsHealthy volunteers can take part
Conditions the study is for: Moderate Hepatic Impairment
What is being tested?: Belzutifan
Type of treatment: Pill or oral medicine
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 17 participants
Where: 2 sitesUnited States
Study dates: 24 Jun 2022to 3 Jan 2024
Phase: Phase 1
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 75 years
All sexes
Healthy volunteers accepted
Adult, Older adult

Who may be able to join

All Participants:
Is in good health.
Has a body mass index (BMI) 18.0-40.0 kg/m^2.
For Participants With Normal Hepatic Function:
Male Participants -Must have been vasectomized or surgically sterilized for at least 4 months or more prior to study intervention administration and agree to the following during the intervention period and for at least 5 days after administration of study intervention, be abstinent from heterosexual intercourse as their preferred and usual lifestyle or must agree to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a woman of childbearing potential (WOCBP) who is not currently pregnant.
Female Participants

Show all 13Show fewer

-Is a woman of non-childbearing potential (WONCBP).
For Participants With Moderate Hepatic Impairment
Has a diagnosis of chronic (>6 months), stable (no acute episodes of illness within the previous 30 days from administration of study intervention due to deterioration in hepatic function) hepatic impairment.
Has a score on the Child-Pugh scale of B (a score of 7-9 on Child-Pugh Score)
Male Participants -Have been vasectomized or surgically sterilized for at least 4 months or more prior to study intervention administration and agree to the following during the intervention period and for at least 5 days after administration of study intervention, be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent or must agree to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a WOCBP who is not currently pregnant.
Female Participants
Must be a WONCBP.

Who cannot join

All Participants:
Is a heavy smoker or heavy user of nicotine-containing products (>20 cigarettes or equivalent/day).
Consumes greater than 3 glasses of alcoholic beverages or equivalent per day.
Consumes excessive amounts, defined as greater than 6 servings of caffeinated beverages per day.
Is a regular user of cannabis, any illicit drugs or has a history of drug (including alcohol) abuse within the last 2 years.
Presents any concern by the investigator regarding safe participation in the study.

Show all 29Show fewer

For Participants with Normal Hepatic Function
Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases.
Is mentally or legally incapacitated, has significant emotional problems or has a history of clinically significant psychiatric disorder of the last 5 years.
Has a history of cancer (malignancy).
Has a history of significant multiple and/or severe allergies (eg, food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability to prescription or nonprescription drugs or food.
Is positive for hepatitis B surface antigen (HBsAg), hepatitis C antibodies, or human immunodeficiency virus (HIV).
Had major surgery, donated or lost 1 unit of blood within the last 4 weeks.
Is unable to refrain from or anticipates the use of any medication, including prescription and nonprescription drugs (with the exception of prescription drugs that are approved by the investigator and Sponsor) or herbal remedies for the prohibited period of time.
Has received any nonlive vaccine starting from 14 days prior to study intervention or is scheduled to receive any nonlive vaccine through 30 days following study intervention. Exception: COVID-19 vaccine may be administered.
Has participated in another investigational study within 4 weeks prior to study intervention administration.
For Participants With Moderate Hepatic Impairment
Is mentally or legally incapacitated, has significant emotional problems or has a history of clinically significant psychiatric disorder in the last 5 years.
Has a history of cancer (malignancy).
Has a history of significant multiple and/or severe allergies (eg, food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability to prescription or nonprescription drugs or food.
Has fluctuating or rapidly deteriorating hepatic function.
Has a history of liver or other solid organ transplantation.
Has transjugular intrahepatic portosystemic shunt and/or has undergone portacaval shunting.
Has encephalopathy Grade 3 or worse within 28 days before administration of study intervention.
Is positive for HIV.
Has had major surgery, donated or lost 1 unit of blood within the last 4 weeks.
Is unable to refrain from or anticipates the use of any medication, including prescription and nonprescription drugs (with the exception of prescription drugs that are approved by the investigator and Sponsor) or herbal remedies for the prohibited period of time.
Has received any nonlive vaccine starting from 14 days prior to study intervention or is scheduled to receive any nonlive vaccine through 30 days following study intervention. Exception: COVID-19 vaccine may be administered.
Has participated in another investigational study within 4 weeks prior to study intervention administration.

Trial locations and contacts

2 sites in 1 country.

United States2 sites

Orlando Clinical Research Center ( Site 0001)
Orlando, Florida, 32809
The Texas Liver Institute ( Site 0002)
San Antonio, Texas, 78215

Other trials in United States

About this study

Official title: An Open-Label, Single-Dose Study to Investigate the Influence of Hepatic Impairment on the Pharmacokinetics of MK-6482

The primary purpose of this study is to compare the plasma pharmacokinetics (PK) of belzutifan (MK-6482) following a single oral 80 mg dose of belzutifan in participants with moderate hepatic impairment to that of healthy matched control participants. This study will also evaluate the safety and tolerability of a single oral 80 mg dose of belzutifan in participants with moderate hepatic impairment.

Conditions: Moderate Hepatic Impairment
Being tested: Belzutifan

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

BelzutifanDrug
Also called MK-6482, PT2977, WELIREG
Two 40 mg tablets given as a single oral 80 mg dose.

Study groups in NCT04995484
Study group	Role	What they receive
Moderate Hepatic Impairment	Experimental	Participants with moderate hepatic impairment will receive a single oral 80 mg dose of belzutifan on Day 1. Receives: Drug: Belzutifan
Healthy	Experimental	Participants with normal hepatic function will receive a single oral 80 mg dose of belzutifan on Day 1. Receives: Drug: Belzutifan

What is being measured

The primary outcome is the main question the study is designed to answer.

Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-Inf) of Belzutifan
AUC0-Inf was defined as the area under the concentration-time curve of belzutifan from time zero to infinity. Blood samples collected predose and at multiple timepoints postdose were used to determine AUC0-Inf of belzutifan.
Measured: Predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96, and 120 hours postdose
Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24hrs) of Belzutifan
AUC0-24hrs was defined as the area under the concentration-time curve of belzutifan from time zero to 24 hours postdose. Blood samples collected predose and at multiple timepoints postdose were used to determine AUC0 to 24 hours of belzutifan.
Measured: Predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24 hours postdose
Maximum Plasma Concentration (Cmax) of Belzutifan
Cmax was defined as the peak level belzutifan reaches in the blood. Blood samples collected predose and at multiple timepoints postdose were used to determine Cmax of belzutifan.
Measured: Predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96, and 120 hours postdose
Time to Maximum Plasma Concentration (Tmax) of Belzutifan
Tmax was defined as the time it took belzutifan to reach its peak level in the blood. Blood samples collected predose and at multiple timepoints postdose were used to determine the Tmax of belzutifan.
Measured: Predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96, and 120 hours postdose
Apparent Terminal Half-life (t1/2) of Belzutifan
Apparent terminal half-life (t1/2) was defined as the time needed to reduce the level of belzutifan in the blood by one-half (1/2). Blood samples collected predose and at multiple timepoints postdose were used to determine the apparent terminal half-life (t1/2) of belzutifan.
Measured: Predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96, and 120 hours postdose

Secondary outcomes (2)

Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE is reported.
Measured: Up to 15 days
Number of Participants Who Discontinue Study Treatment Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued the study due to an AE is reported.
Measured: Up to 15 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

24 Jun 20223 Jan 2024

First posted9 Aug 2021
Study start24 Jun 2022
Primary completion25 Dec 2023
Study completion3 Jan 2024

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Other trials for Moderate Hepatic ImpairmentStudies of the same condition, open and under way.
More trials run by Merck Sharp & Dohme LLCThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 1
Primary purpose: Treatment
Allocation: Non-randomised
Intervention model: Parallel groups
Model description: Parallel Group
Masking: None (open label)
Enrolment: 17 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT04995484
Sponsor's protocol ID: 6482-020
Other IDs: MK-6482-020
Status last verified: Nov 2024
First submitted: 2 Aug 2021
Last updated: 13 Jan 2025
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: Yes: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Not yet recruitingPhase 1
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Tacabrutideg (BGB-16673) in Participants With Moderate and Severe Hepatic Impairment
Hepatic Impairment, Healthy Adult Participants
RecruitingPhase 1
A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234
Hepatic Impairment
Not yet recruitingPhase 1
Aleniglipron Hepatic Impairment Study
Hepatic Impairment
RecruitingPhase 1
A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems
Healthy, Hepatic Impairment
Not yet recruitingPhase 1
A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic Impairment
Hepatic Insufficiency, Liver Diseases

All Moderate Hepatic Impairment trials

Study at a glance

From the registry record, last updated by the sponsor on 13 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: An Open-Label, Single-Dose Study to Investigate the Influence of Hepatic Impairment on the Pharmacokinetics of MK-6482
ClinicalTrials.gov ID: NCT04995484
Acronym / sponsor ID: 6482-020
Conditions: Moderate Hepatic Impairment
Phase: Phase 1
Study type: Interventional
Recruitment status: Completed
Enrolment: 17 participants (actual)
Lead sponsor: Merck Sharp & Dohme LLCIndustry (pharma, biotech, devices)
Study start: 24 Jun 2022 (actual)
Primary completion: 25 Dec 2023 (actual)
Study completion: 3 Jan 2024 (actual)
First posted: 9 Aug 2021 (actual)
Results: Posted 13 Jan 2025

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose: Treatment
Allocation: Non-randomised
Intervention model: Parallel groups
Masking: None (open label)
Number of arms: 2
Model description: Parallel Group

Arm	Type	Receives
Moderate Hepatic Impairment	Experimental	Drug: BelzutifanParticipants with moderate hepatic impairment will receive a single oral 80 mg dose of belzutifan on Day 1.
Healthy	Experimental	Drug: BelzutifanParticipants with normal hepatic function will receive a single oral 80 mg dose of belzutifan on Day 1.

Who may qualify

Ages: 18 to 75 years
Sex: All
Healthy volunteers: Accepted
Age groups: Adult, Older adult

Key inclusion criteria (13 listed)

Is in good health.
Has a body mass index (BMI) 18.0-40.0 kg/m^2.
Male Participants -Must have been vasectomized or surgically sterilized for at least 4 months or more prior to study intervention administration and agree to the following during the intervention period and for at least 5 days after administration of study intervention, be abstinent from heterosexual intercourse as their preferred and usual lifestyle or must agree to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a woman of childbearing potential (WOCBP) who is not currently pregnant.
Female Participants
-Is a woman of non-childbearing potential (WONCBP).

Key exclusion criteria (29 listed)

Is a heavy smoker or heavy user of nicotine-containing products (>20 cigarettes or equivalent/day).
Consumes greater than 3 glasses of alcoholic beverages or equivalent per day.
Consumes excessive amounts, defined as greater than 6 servings of caffeinated beverages per day.
Is a regular user of cannabis, any illicit drugs or has a history of drug (including alcohol) abuse within the last 2 years.
Presents any concern by the investigator regarding safe participation in the study.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
BelzutifanAlso: MK-6482, PT2977, WELIREGTwo 40 mg tablets given as a single oral 80 mg dose.	Drug	Healthy, Moderate Hepatic Impairment

Primary outcome

Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-Inf) of Belzutifan
Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96, and 120 hours postdose
AUC0-Inf was defined as the area under the concentration-time curve of belzutifan from time zero to infinity. Blood samples collected predose and at multiple timepoints postdose were used to determine AUC0-Inf of belzutifan.
Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24hrs) of Belzutifan
Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24 hours postdose
AUC0-24hrs was defined as the area under the concentration-time curve of belzutifan from time zero to 24 hours postdose. Blood samples collected predose and at multiple timepoints postdose were used to determine AUC0 to 24 hours of belzutifan.
Maximum Plasma Concentration (Cmax) of Belzutifan
Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96, and 120 hours postdose
Cmax was defined as the peak level belzutifan reaches in the blood. Blood samples collected predose and at multiple timepoints postdose were used to determine Cmax of belzutifan.
Time to Maximum Plasma Concentration (Tmax) of Belzutifan
Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96, and 120 hours postdose
Tmax was defined as the time it took belzutifan to reach its peak level in the blood. Blood samples collected predose and at multiple timepoints postdose were used to determine the Tmax of belzutifan.
Apparent Terminal Half-life (t1/2) of Belzutifan
Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96, and 120 hours postdose
Apparent terminal half-life (t1/2) was defined as the time needed to reduce the level of belzutifan in the blood by one-half (1/2). Blood samples collected predose and at multiple timepoints postdose were used to determine the apparent terminal half-life (t1/2) of belzutifan.

2 secondary outcomes

Number of Participants Who Experience an Adverse Event (AE)
Time frame: Up to 15 days
Number of Participants Who Discontinue Study Treatment Due to an AE
Time frame: Up to 15 days

Results and safety

Results posted to the registry on 13 Jan 2025, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Moderate Hepatic Impairment	9	9
Healthy	8	8

Primary outcome: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-Inf) of Belzutifan

Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96, and 120 hours postdose. Geometric mean (Geometric Coefficient of Variation). Unit: ng*hr/mL

Measure	Moderate Hepatic Impairment n = 9	Healthy n = 8
Value	22500 (80.3)	14800 (35.1)

Moderate Hepatic Impairment vs Healthy: Geometric Mean Ratio: 1.52 (90% CI 0.95 to 2.43)

Population analysed: All participants who comply with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, who have available measurement data, and have no important protocol deviations.

Primary outcome: Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24hrs) of Belzutifan

Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24 hours postdose. Geometric mean (Geometric Coefficient of Variation). Unit: ng*hr/mL

Measure	Moderate Hepatic Impairment n = 9	Healthy n = 8
Value	10500 (34.5)	9650 (28.8)

Moderate Hepatic Impairment vs Healthy: Geometric Mean Ratio: 1.09 (90% CI 0.84 to 1.42)

Primary outcome: Maximum Plasma Concentration (Cmax) of Belzutifan

Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96, and 120 hours postdose. Geometric mean (Geometric Coefficient of Variation). Unit: ng/mL

Measure	Moderate Hepatic Impairment n = 9	Healthy n = 8
Value	852 (28.7)	870 (31.4)

Moderate Hepatic Impairment vs Healthy: Geometric Mean Ratio: 0.98 (90% CI 0.76 to 1.26)

Primary outcome: Time to Maximum Plasma Concentration (Tmax) of Belzutifan

Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96, and 120 hours postdose. Median (Full Range). Unit: hr

Measure	Moderate Hepatic Impairment n = 9	Healthy n = 8
Value	2.00 (0.50 to 3.00)	2.00 (1.00 to 3.00)

2 secondary outcomes are reported in the full results.

Adverse events

Time frame: Up to 15 days. Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Moderate Hepatic Impairment	0 of 9 (0%)	1 of 9 (11.1%)	0 of 9
Healthy Matched Control	0 of 8 (0%)	1 of 8 (12.5%)	0 of 8

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 13 Jan 2025.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Merck Clinical Trials InformationLink provided by the sponsor.
Individual participant dataSharing planned: Yes. http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Related trials for Moderate Hepatic Impairment

Not yet recruitingPhase 1
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Tacabrutideg (BGB-16673) in Participants With Moderate and Severe Hepatic Impairment
Hepatic Impairment, Healthy Adult Participants
RecruitingPhase 1
A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234
Hepatic Impairment
Not yet recruitingPhase 1
Aleniglipron Hepatic Impairment Study
Hepatic Impairment
RecruitingPhase 1
A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems
Healthy, Hepatic Impairment
Not yet recruitingPhase 1
A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic Impairment
Hepatic Insufficiency, Liver Diseases

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Medical Director study director

Merck Sharp & Dohme LLC

2 sites in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Belzutifan in people with Moderate Hepatic Impairment, run by Merck Sharp & Dohme LLC at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 13 inclusion and 29 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 13 Jan 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-Inf) of Belzutifan (time frame: Predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96, and 120 hours postdose). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04995484.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2025.